eczema
Eczema drug Kymera succeeds in first trial, could rival Dupixent
Kymera Therapeutics announced Monday that, for the second time this year, it had successfully completed an early trial of a closely watched drug intended to rival Sanofi and Regeneron’s blockbuster treatment Dupixent. The phase 1 BroADen study enrolled 22 patients with moderate to severe eczema (atopic dermatitis), all of whom took Kymera’s investigational pill, KT-621. […]
1 min read
Apogee Therapeutics reports the first data on the drug in long -term eczema
Adam Feuerstein is a main writer and biotechnology columnist, reporting on the crossroads of drug development, business, Wall Street and biotechnology. He is also co-host of the weekly biotech podcast The Readout Loud and author of the Biotech dashboard of the Adam newsletter. You can reach Adam on the signal to stataf.54. Apogee Therapeutics said […]
1 min read